**Cornea and Glaucoma**

tric oxide and inducible nitric oxide synthase gene expression after spinal cord

[82] Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler L.A and Schwartz M. Vaccination for protection of retinal ganglion cells against death from glutamate cy‐ totoxicity and ocular hypertension: Implications for glaucoma Proc Natl Acad Sci U S

[84] Husain S, Potter DE, Crosson CE. Opioid receptor-activation: retina protected from

[85] Husain S, Abdul Y, Potter DE. Non-Analgesic Effects of Opioids: Neuroprotection in the Retina Curr Pharm Des. 2012 Jun 28. [Epub ahead of print] http://

[86] Bull ND, Irvine KA, Franklin RJ, Martin KR. Transplanted oligodendrocyte precursor cells reduce neurodegeneration in a model of glaucoma. Invest Ophthalmol Vis Sci.

[87] Tatton WG.Apoptotic mechanisms in neurodegeneration: possible relevance to glau‐

[88] Qi X, Sun I, Lewin AS, et al. Long term suppression of neurodegeneration in chronic experimental optic neuritis:anti-oxidant gene therapy. Invest Ophthalmol Vis Sci

[89] Borrás T.Advances in glaucoma treatment and management: gene therapy. Invest

[90] Di Polo A, Aigner LJ, Dunn RJ, et al. Prolonged delivery of brain derived neurotro‐ phic factor by adenovirus infected Muller cells temporarily rescues injured retinal

[83] Nilforushan N. Neuroprotection in glaucoma.J Ophthalmic Vis Res. 2012;7:91-3

www.ncbi.nlm.nih.gov/pubmed/22747547 (last access August 5th 2012)

injury. J Neurosci Res. 2012;90:656-63. doi: 10.1002/jnr.22771

ischemic injury. Invest Ophthalmol Vis Sci. 2009;50:3853-9

coma. Eur J Ophthalmol. 1999 Jan-Mar;9 Suppl 1:S22-9

ganglion cells. Pro Natl Acad Sci USA. 1998;95:3978-83

Ophthalmol Vis Sci. 2012 4;53:2506-10.

A. 2001; 98: 3398–3403

226 Glaucoma - Basic and Clinical Aspects

2009;50:4244–4253

2007;48:5360-70

Gema Bolivar, Javier Paz Moreno-Arrones and Miguel A. Teus

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53017
